T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Biogen
BIIB
$30.9B
| $271M | 0.02% |
1,131,357
-652,779
| -37% | -$168M |
|
477
Reliance Steel & Aluminium
RS
$21.8B
| $270M | 0.02% |
1,665,545
+30,251
| +2% | +$4.68M |
|
478
3M
MMM
$94.8B
| $269M | 0.02% |
1,813,850
-1,269,066
| -41% | -$189M |
|
479
American Express
AXP
$232B
| $269M | 0.02% |
1,646,225
-58,576
| -3% | -$9.99M |
|
|
NLSN
480
DELISTED
Nielsen Holdings plc
NLSN
| $268M | 0.02% |
13,090,058
-2,934,567
| -18% | -$59.8M |
|
481
PPG Industries
PPG
$25.5B
| $268M | 0.02% |
1,556,839
-3,363,319
| -68% | -$540M |
|
482
Invesco Senior Loan ETF
BKLN
$6.75B
| $267M | 0.02% |
12,095,600
-2,365,900
| -16% | -$52.2M |
|
483
Constellation Brands
STZ
$22.9B
| $266M | 0.02% |
1,058,617
+732,982
| +225% | +$167M |
|
484
Post Holdings
POST
$3.65B
| $265M | 0.02% |
3,597,428
-90,544
| -2% | -$6.21M |
|
485
Lennox International
LII
$14.5B
| $264M | 0.02% |
812,607
-18,248
| -2% | -$5.7M |
|
486
SPX Corp
SPXC
$10.9B
| $263M | 0.02% |
4,403,455
+78,062
| +2% | +$4.73M |
|
487
Saia
SAIA
$9.73B
| $258M | 0.02% |
766,605
-46,209
| -6% | -$14.3M |
|
488
Simon Property Group
SPG
$71.4B
| $258M | 0.02% |
1,616,015
-121,722
| -7% | -$18.6M |
|
489
VF Corp
VFC
$5.73B
| $256M | 0.02% |
3,500,715
+82,679
| +2% | +$6.04M |
|
|
KRTX
490
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $256M | 0.02% |
1,955,366
+114,735
| +6% | +$14.8M |
|
491
National Fuel Gas
NFG
$7.77B
| $256M | 0.02% |
4,000,211
+92,918
| +2% | +$5.55M |
|
492
Cognex
CGNX
$10.2B
| $255M | 0.02% |
3,278,413
-73,040
| -2% | -$5.89M |
|
493
Landstar System
LSTR
$6.31B
| $255M | 0.02% |
1,423,663
-32,732
| -2% | -$5.61M |
|
494
Albemarle
ALB
$15.1B
| $254M | 0.02% |
1,084,547
+186,277
| +21% | +$46.1M |
|
495
Vodafone
VOD
$37.2B
| $252M | 0.02% |
16,911,836
+2,539,421
| +18% | +$38.8M |
|
496
UFP Industries
UFPI
$5.06B
| $252M | 0.02% |
2,736,216
-42,369
| -2% | -$3.56M |
|
497
PROG Holdings
PRG
$1.64B
| $252M | 0.02% |
5,578,830
-344
| -0% | -$15.5K |
|
498
Graco
GGG
$13.4B
| $251M | 0.02% |
3,110,200
-156,245
| -5% | -$11.9M |
|
|
APLS
499
DELISTED
Apellis Pharmaceuticals
APLS
| $251M | 0.02% |
5,298,491
+491,414
| +10% | +$19.3M |
|
500
Intellia Therapeutics
NTLA
$1.69B
| $248M | 0.02% |
2,100,348
-244,190
| -10% | -$30.6M |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.